Since M Midostaurin appears to be a very potent inhibitor based on the docking results, I examined the molecule more closely. There are three separate M Midostaurin molecules in the current QF FDA-approved database, which consists of 1,599 drugs. Two of them are 3-Hydroxy Midostaurin, and they not only share the same name but also the same CAS number, 179237-49-1. These molecules are stereoisomers, as illustrated in the picture below. The S stereoisomer of 3-Hydroxy Midostaurin is more active because its OH group is oriented toward the GLU166 residue, allowing it to form an additional strong hydrogen bond. This S stereoisomer consistently appears at the top of the hitlists for both QFVina and QFVinardo. The interaction between this stereoisomer and the 6Y2G target protein, as determined by the QFVinardo method, is illustrated below in both 2D and 3D visualizations. These images highlight all the important intermolecular interactions between the ligand and the protein. Notably, Midostaurin has been suggested for drug repurposing to treat COVID-19 patients . These docking results strongly indicate that the S stereoisomer of the 3-Hydroxy Midostaurin may effectively inhibit the COVID-19 protein, and I recommend further experimental testing to explore this potential.